Form 8-K - Current report:
SEC Accession No. 0000950170-25-087486
Filing Date
2025-06-17
Accepted
2025-06-17 17:00:32
Documents
10
Period of Report
2025-06-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trvi-20250611.htm   iXBRL 8-K 106112
  Complete submission text file 0000950170-25-087486.txt   216725

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20250611.xsd EX-101.SCH 26440
12 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20250611_htm.xml XML 4711
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 251054129
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)